Document |
Document Title |
WO/2023/223962A1 |
Provided is a surface-modified nanodiamond that can selectively accumulate a sufficient amount of boron atoms in cancer tissues or cancer cells and can efficiently kill or injure cancer cells. The surface-modified nanodiamond of the pr...
|
WO/2023/225634A2 |
Provided herein is the use of LSD1 inhibitors, in particular bomedemstat, in connection with use and manufacture of immune effector cells such as NK cells and T cells engineered to express a chimeric antigen receptor (CAR), to treat a su...
|
WO/2023/220527A2 |
The present disclosure relates to method of treating stress urinary incontinence in a female subject, with endoscopic reconstruction of the external urinary sphincter using injection of a bulking agent. The reconstruction of the external...
|
WO/2023/220637A2 |
An intravascular device including a transferable drug coating adhered to an exposed outer surface on the device, the drug coating comprising an anti-proliferative active ingredient and a xanthophyll excipient. The xanthophyll may be sele...
|
WO/2023/220648A2 |
Provided are methods for detecting urogenital malignancies in dogs. In some embodiments, the methods include identifying a deletion or single nucleotide substitution within a BRAF gene and/or within a MAP2K1 gene present in or isolated f...
|
WO/2023/220631A2 |
As disclosed herein, sotorasib augments the KRAS-G12C mutant cancer cells response to TNFα by increasing TNFR1 surface expression, which in turn upregulates TNFα and IFNγ down-stream target genes and ultimately enhances cancer cell de...
|
WO/2023/217093A1 |
Provided herein pertains to the biomedical field, and particularly relates to a method for activating N-oxide prodrugs with radiation, and a method of treating or suppressing a cancer, reducing its severity, lowering its risk or inhibiti...
|
WO/2023/219958A2 |
Provided herein are methods for treating a disease or condition associated with one or more of: mtDNA fragmentation; cytostolic Ox-mtDNA; mtDNA release; or Caspl activation and IL-ip production by administering an effective amount of an ...
|
WO/2023/217952A1 |
The present invention relates to calibrated dual-phase nanodroplets comprising an outer layer and an inner core, said outer layer comprising a biocompatible fluorinated surfactant and said inner core comprising a fluorinated compound and...
|
WO/2023/215913A2 |
Compositions and methods for the diagnosis and treatment of severe Covid 19 and other inflammatory autoimmune disorders are disclosed.
|
WO/2023/215514A2 |
Provided herein are systems, methods, and compositions for bioluminescence-triggered catalysis of bioorthogonal labeling chemistries in a proximity dependent manner. In particular, provided herein are bioluminescent proteins or complexes...
|
WO/2023/207746A1 |
Provided are an asymmetric donor-receptor type near-infrared region II probe molecule, a method for preparing same, and use thereof. The probe molecule is represented by the following general formula (1). The emission spectrum of the pro...
|
WO/2023/209709A1 |
Disclosed herein are combination therapies including apoptotic cells combined with at least one chemotherapeutic agent for the treatment of cancers, including mesothelioma. Effective treatment is observed using apoptotic cells freshly pr...
|
WO/2023/210645A1 |
[Problem] To provide: an ICG lipid derivative that can form lipid microparticles having excellent stability and/or capable of releasing a drug in a selective manner; and lipid microparticles each containing the ICG lipid derivative. [Sol...
|
WO/2023/211893A1 |
A photothermal magnetic resonance imaging enhancement agent includes composite nanoparticles. The composite nanoparticle includes an inner layer of a dielectric material with a porous substrate having pores, an inner layer with a core, m...
|
WO/2023/205802A2 |
Senescent cells are implicated in aspects of age-related decline in health and contribute to many diseases. Cells can be transformed into a senescent state upon prolonged exposure to the Senescence-Associated Secretory Phenotype (SASP) f...
|
WO/2023/205099A2 |
Here, we describe an infant with congenital dilated cardiomyopathy (cDCM) whose impaired cardiac function and disrupted sarcomere and mitochondria structures were modeled using induced pluripotent stem cells (iPSCs). The causal gene enco...
|
WO/2023/205785A2 |
The present disclosure generally relates to compositions and methods for targeting pro-survival signaling hubs in anoikis-resistant cells, such as anoikis-resistant cancer cells. Embodiments also include methods of changing morphology of...
|
WO/2023/201873A1 |
Disclosed are a BODIPY-based diamond-shaped metal ring, and a method for preparing same, and use thereof in near-infrared emission. According to the present invention, a BODIPY-based 120-degree bipyridine BODIPY ligand molecule 1 having ...
|
WO/2023/202092A1 |
Disclosed in the present invention are a nanoparticle capable of releasing carbon monoxide in a responsive manner, a preparation method therefor and the use thereof. The nanoparticle comprises a shell and an inner core, wherein the shell...
|
WO/2023/204581A1 |
The present invention relates to a three-dimensional hydrogel composite having cancer cell targeting and cancer cell killing effects, and a method for manufacturing same, and more specifically, to: a three-dimensional hydrogel composite ...
|
WO/2023/201312A2 |
The present application provides compounds and methods for treating ocular fibrotic pathologies, including using dopamine D2 receptor antagonists for treating proliferative vitreoretinopathy.
|
WO/2023/196405A1 |
Boronated prodrugs have been developed that are particularly advantageous for use in boron proton capture therapy (BPCT) and boron neutron capture therapy (BNCT). Cancer-targeting moieties, such as heptamethine cyanine dyes (HMCDs), are ...
|
WO/2023/196086A2 |
The present invention relates to combination therapies for treating cancers associated with genetic alterations of the MAPK pathway and/or EGFR In particular, the present invention relates to methods of treating cancer in a subject in ne...
|
WO/2023/196218A2 |
The present invention relates to combination therapies for treating cancers associated with genetic alterations of the MAPK pathway and/or EGFR. In particular, the present invention relates to methods of treating cancer in a subject in n...
|
WO/2023/196978A2 |
Provided herein are methods of identifying a subject with prostate cancer (such as a human or veterinary subject) who will respond to enzalutamide therapy. In particular examples, the methods can determine with high accuracy whether a su...
|
WO/2023/196584A2 |
The application relates to methods for treating chronic pain involving administering to a subject in need thereof a therapeutically effective amount of an inhibitor of endocytosis.
|
WO/2023/196821A2 |
The use of GUCY2C agonists in combination with PDE3 inhibitors in methods of treating the individual who has been identified as experiencing chronic visceral pain or in methods of suppressing appetite are disclosed. Compositions or kits ...
|
WO/2023/196891A2 |
The present invention provides a method for increasing the efficacy of an anticancer therapy by administering to a subject in need thereof at least one compound that at least partially blocks the activity of a bacterial DnaK, and pharmac...
|
WO/2023/196820A2 |
The present disclosure provides, among other things, specific doses of an ENPP1 agent for in vivo treatment of an ENPP1 deficiency, such as for treatment of Generalized Arterial Calcification of Infancy (GACI), Autosomal Recessive Hypoph...
|
WO/2023/196952A2 |
Provided herein is a method for treating a disorder ameliorated by muscarinic receptor activation in a patient in need thereof, comprising administering to the patient a muscarinic orthosteric agonist, such as xanomeline and/or a salt th...
|
WO/2023/196576A2 |
This invention discloses methods of diagnosing and compositions for treating a human subject suspected of having a neurological or hematological disease. Also disclosed are proteins which serve as effective biomarkers for confirming the ...
|
WO/2023/193416A1 |
The present invention relates to the field of biomedicine, and specifically, discloses a near-infrared-responsive injectable microsphere capable of treating a cancer by combining chemotherapy with photothermal therapy and a method for pr...
|
WO/2023/194896A1 |
5-amminolevulinic acid and/or the salts thereof for use in mandibular bone regeneration, in combination with the application of light radiation, wherein the bone regeneration is determined by an increase in the proliferation of osteoblas...
|
WO/2023/192955A2 |
Disclosed herein are compositions and methods for treating cancer. The methods can comprise administrating to a subject with cancer a therapeutically effective amount of an oncolytic virus and a therapeutically-effective amount of a nucl...
|
WO/2023/133058A9 |
Disclosed are methods of treating an ocular disease associated with retinal ischemic injury in a subject comprising administering to the subject a p75NTR modulator, a MSC comprising decreased p75NTR expression or activity or a MSC secrel...
|
WO/2023/192938A2 |
The current disclosure provides for methods for diagnosing, prognosing, and treating cerebral cavernous malformations (CCMs). Also provided are methods for determining the efficacy of therapeutic treatments for CCM, such as those that ma...
|
WO/2023/187176A1 |
The invention concerns an in vitro or ex vivo method for delivering a cargo into a cell, the method comprising: - contacting a cell with one or more photoresponsive organic particles and a cargo, wherein the organic particle is selected ...
|
WO/2023/186737A1 |
Photodynamic light therapy apparatus and methods for treating oral disease are disclosed where one method for reducing or eliminating microbial biofilm or plaque and inflammation in a microbial infected area of the mouth generally compri...
|
WO/2023/192815A2 |
Methods of data analysis, methods of detection, methods of treatment, compositions, and kits associated with treatment of diarrheal disorders are disclosed herein. Inventive concepts disclosed herein can assist stake holders in relieving...
|
WO/2023/192988A2 |
The technology described herein is directed to immune modulatory agents and methods of use. In some aspects, described herein are agents that modulate IL-17a/IL-17 receptor- induced signalling and/or IL-17f/IL-17 receptor-induced signall...
|
WO/2023/192220A2 |
The present disclosure provides methods and systems for diagnosing and treating fibromyalgia in a patient. In one method, an oxygenation level at a muscle location is obtained for the patient; and fibromyalgia is diagnosed in the patient...
|
WO/2023/192639A2 |
In one aspect, methods of treating cancer are provided that comprise: administering to a subject a composition comprising a therapeutically effective amount of: a first agent which inhibits programmed death 1 (PD-1) expression or functio...
|
WO/2023/192779A2 |
The present application relates to the prevention and treatment of respiratory illnesses due to RNA virus infection in patients in need thereof. The application includes compositions of matter, pharmaceutical compositions, combinations, ...
|
WO/2023/192880A2 |
Disclosed herein are methods for treating, ameliorating and/or preventing fibrodysplasia sssificans progressiva (FOP) in a subject in need thereof. The methods include downregulating matrix metalloproteinase 9 (MMP-9) level and/or activi...
|
WO/2023/192653A1 |
The present disclosure provides photocleavable rhodamine probes that facilitate live- and fixed-cell immunofluorescence. The ultra-fast spirocyclization of the dye following cleavage depletes the fluorescence signal, enabling cyclic mult...
|
WO/2023/182317A1 |
The purpose of the present invention is to provide a novel compound which can serve as a component of a boron pharmaceutical agent. The present application provides a boron-containing modified polyrotaxane comprising a plurality of cyclo...
|
WO/2023/179866A1 |
The present invention relates to means for transiently disrupting the neurovascular barrier of a human. More particularly, the invention relates to ultrasound contrast agent for use in treating Amyotrophic Lateral Sclerosis (ALS) in a su...
|
WO/2023/178878A1 |
A microneedle patch for enhancing an accumulation of protoporphyrin IX in a solid tumor and a preparation method therefor. The method comprises the steps of: dissolving albumin in a Dulbecco's culture medium, using the albumin as a templ...
|
WO/2023/183776A2 |
The present disclose provides methods for treating neuroinflammation. Compositions having therapeutic agents targeted to interfering with succinate/succinate receptor signaling are administered to reduce or ameliorate neuroinflammation. ...
|